Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients
ISRN Hepatology · 2013
DOI: 10.1155/2013/412317 ↗Abstract
Interleukin-10 (IL-10) and interleukin-6 (IL-6) have been reported to be related to hepatocellular carcinoma (HCC) prognosis. This study aimed to investigate the clinical usefulness of serum levels of IL-6 and IL-10 as biomarkers for HCC among high-risk patients. Materials and Methods . 80 individuals were enrolled in this study; they were categorized into 4 groups: group 1 healthy individuals (NC) ( n = 20 ), group 2 chronic hepatitis C virus (HCV) patients ( n = 20 ), group 3 cirrhotic patients (LC) ( n = 20 ), and HCC group ( n = 20 ). Using ELISA technique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups. Results . The mean serum levels of IL-6 were significantly higher in HCC than in LC, HCV, and NC groups ( 13.99 ± 1.80 , 7.49 ± 0.43 , 5.78 ± 0.74 , and 2.57 ± 0.31 ), respectively ( P < 0.05 ); also the serum levels of IL-10 were significantly higher in HCC compared with LC, HCV, and NC groups ( 13.69 ± 1.89 , 7.37 ± 0.53 , 5.18 ± 0.6 , and 3.31 ± 0.42 ) ( P < 0.05 ). We also found that the tumor size is correlated strongly with IL-6 and IL-10 levels ( r = 0.925 , P < 0.001 ; r = 0.821 , P < 0.001 ), respectively. Conclusion . The combination of those markers may help to identify a group of HCC patients with low AFP.
EUVIMED